ABSTRACT
INTRODUCTION
. Smoking status was characterized as "never" (less than 1 pack year of smoking history), "former" (at least one pack year of smoking history who quit smoking at least 12 month prior to presentation), or "current" (at least one pack year of smoking who are either still smoking or quit less than a year prior to presentation). Seventy-six patients received treatment during the study period, either with corticosteroids alone (n = 37), cyclophosphamide alone (n = 15), or corticosteroids and cyclophosphamide (n = 24). A second group of 51 patients with 12 month change data were also analyzed. These patients were largely a subset of the original 81 patients seen at 6 months. Informed consent was obtained, and the Institutional Human Subject Review Committee approved the protocol.
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Clinical Evaluation
Patients were questioned regarding the amount of exertion required to precipitate dyspnea. Degree of dyspnea was scored from 0 to 20, with a higher score indicating more severe dyspnea. (17) Pulmonary function testing and arterial blood gas sampling included measurement of thoracic gas volume, residual volume, total lung capacity, forced vital capacity, forced expiratory volume in 1 second, single-breath diffusing capacity for carbon monoxide, arterial pH, partial pressure of oxygen, partial pressure of carbon dioxide, serum bicarbonate, and oxygen saturation. 
Histopathology
All patients underwent surgical lung biopsy. All biopsies had been previously reviewed by a pulmonary pathologist familiar with the current histopathologic criteria for UIP and the diagnosis of UIP confirmed. Other histopathologic patterns including nonspecific interstitial pneumonia, organizing pneumonia, diffuse alveolar damage, respiratory bronchiolitis, desquamative interstitial pneumonia, and lymphocytic interstitial pneumonia were excluded. 
RESULTS
Baseline Demographics
There were 81 patients with 6-month follow up data. Their clinical and physiologic data are summarized in Tables 1 and 2 . Mean age at presentation was 61.5 years. The male to female ratio was approximately 5:3. There were 15 (18.5%) current smokers, 36 (44.4%) former smokers and 30 (37.0%) never smokers. The 12 month follow up group was similar in baseline demographics (data not shown).
Overall Survival
Median survival in the 6 month group was 4.3 years (25 th and 75 th percentiles were 1.7 and 9.7 years respectively). There were 54 deaths due to IPF during the study period. years respectively).
Change Variables and Survival Time
Clinical Variables
Baseline dyspnea score was predictive of survival time, as previously reported. (6) The change in dyspnea score over 6 months was predictive of survival time and remained so after adjusting for baseline score (see Table E1 in the on-line data supplement). Change in dyspnea score over 12 months was also predictive of survival time. The estimated 5 year survival rates for an average patient (average age and baseline dyspnea score) with a clinically relevant increase (2 points or more), decrease (2 points or more) or no change (less than two point increase or decrease) in dyspnea score over 6 months are shown in Table 3 , stratified by smoking status. Kaplan-Meier curves were constructed to illustrate differences in survival based on these three categories of change in dyspnea score ( Figure   1 ).
Pulmonary Function Testing Variables
Baseline measurements of total lung capacity (TLC) % predicted, thoracic gas volume (Vtg) % predicted, forced vital capacity (FVC) % predicted, forced expiratory volume in 1 second (FEV1) % predicted, and single-breath diffusing capacity for carbon monoxide (DLCO) % predicted were predictive of survival time as previously reported. (6) The 8 changes in TLC % predicted, Vtg % predicted, FVC % predicted, FEV1 % predicted, and DLCO % predicted over 6 months were predictive of survival time and remained so when adjusted for baseline values (see Table E1 in the on-line data supplement). Changes in TLC % predicted and FVC % predicted over 12 months were also predictive of survival time. Of these variables, FVC % predicted was the best predictor based on model fit
comparison (see Table E2 in the on-line data supplement). The estimated 5 year survival rates for an average patient (average age and baseline FVC % predicted) with a clinically relevant increase (10 percent or more), decrease (10 percent or more) or no change (less than ten percent increase or decrease) in FVC % predicted over 6 months are shown in Table 4 , stratified by smoking status. Kaplan-Meier curves were constructed to illustrate differences in survival based on these three categories of change in FVC % predicted ( Figure 2 ).
Arterial Blood Gas Variables
Baseline measurement of partial pressure of oxygen (PaO2), O2 saturation, and alveolararterial oxygen gradient (AaPO2) were predictive of survival time as previously reported.
(6) The changes in PaO2, O2 saturation and AaPO2 over 6 months were predictive of survival time after adjustment for baseline value (see Table E1 in the on-line data supplement). Changes in PaO2, O2 saturation and AaPO2 over 12 months were also predictive of survival time. Of these variables, AaPO2 was the best predictor based on model fit comparison (see Table E2 in the on-line data supplement). The estimated 5 year survival rates for an average patient (average age and baseline AaPO2) with a clinically relevant increase (5 mmHg or more), decrease (5 mmHg or more) or no change (less than 9 5 mmHg increase or decrease) in AaPO2 over 6 months are shown in Table 5 , stratified by smoking status. Kaplan-Meier curves were constructed to illustrate differences in survival based on these three categories of change in AaPO2 ( Figure 3 ).
DISCUSSION
Changes in several easily measured clinical and physiologic variables over 6 and 12 months are statistically significant predictors of survival time in IPF. Symptom-based dyspnea scores, pulmonary function testing, and arterial blood gas analysis are widely available and highly reproducible. Measurement of these variables can be obtained in most practices quickly, and provide the practicing clinician with powerful prognostic information. Importantly, changes in these variables predict survival even after adjustment for the variables' baseline measurements, suggesting that the rate of progression, independent of the initial degree of disability, is important for determining prognosis. Based on model fit comparison analysis and clinical utility, the most powerful predictors appear to be dyspnea score, FVC % predicted, and AaPO2.
Predicting survival time in patients with IPF has been the focus of much study over the last thirty years. (6-16) Interpretation of this literature is difficult for several reasons. There are several potential sources of bias in our study. There is by definition a selection bias for healthier patients given the requirement that patients live to at least 6 (or 12) months of follow up to be included in the study. This bias likely explains why the median survival time of this cohort (4.3 years for the 6 month group and 6.2 years for the 12 month group) is longer than that seen in a general population of IPF patients (2-3 years).
Baseline values of TLC % predicted, FVC % predicted and FEV1 % predicted were higher in this cohort when compared to a larger cohort of patients with biopsy-proven IPF that included patients who died prior to 6 month follow up (data not shown). Baseline age, smoking status, dyspnea score and arterial blood gas values were not substantially different. A second possible bias is related to loss to follow-up. While patients were asked to return for 6 and 12 month visits, there was clearly a proportion (increasing over time) that elected not to return, even when follow-up calls revealed that patients were still alive at the time in question. All patients were seen at a tertiary care center specializing in interstitial lung disease, adding potential referral bias.
Our study also censored patients dying from causes of death other than IPF. An argument can be made that the more clinically meaningful endpoint is "all cause death" and not "death due to IPF." To assess the sensitivity of our findings to censoring, statistical analyses were repeated for the recommended predictors (dyspnea score, FVC % predicted Subjects are stratified by smoking status (see methods). Predicted 5 year survival rates are based on the average subject, age 61.5 years and dyspnea score 10.2 at presentation. Subjects are stratified by smoking status (see methods). Predicted 5 year survival rates are based on the average subject, age 61.5 years and forced vital capacity % predicted of 62.7 at presentation. without an identifiable alternative cause of death were considered to have died from IPF.
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Sensitivity to Censoring Analyses:
For the variables dyspnea score, FVC % predicted, and AaPO2, analyses were re-run without censoring the 5 deaths that were not due to IPF, thus examining the sensitivity of the analyses to time to death as opposed to time to death due to IPF. As parameter estimates were little changed by this re-definition of end-point, analyses were not shown.
Survival Models: Cox's proportional hazards models were used to determine the effect of 6 month and12 month change variables on survival time, adjusting for age (modeled continuously) and smoking status (modeled as a stratification variable due to lack of proportional hazards). The effect of a unit change in each changed variable was evaluated individually, with and without adjustment for baseline value. Hazard ratios, the relative amount of risk associated with a unit increase in the explanatory variable, are reported for the age, smoking, and baseline adjusted analyses (Table E1) . where ln indicates the natural log For example, for a decrease of 10% in FVC % predicted over 6 months, the calculation is as follows:
hazard ratio for change (-10) = e [(-10) * ln(0.934)] = e 0.66 = 1.98
Model Fit Comparisons:
In an effort to determine which of the clinical and physiological parameters best predicted survival time, -2 log likelihood statistics were calculated on the subset of 68 subjects that had complete data for all change variables except for DLCO, DLCO/VA and HCO3. These three variables were excluded from this model comparison as change data were less complete. All models included the 6 month change variable, its 57 baseline value, age and smoking history. Results of this analysis are summarized in Table   E2 .
Predicted Survival Times: For the variables dyspnea score, FVC % predicted, and AaPO2, estimated 5 year survival times were calculated. As the Cox proportional hazards models were stratified by smoking history, predictions were made separately by smoking status. These predicted survival times are based on an average aged subject (61.5) with the average baseline value of the variable being addressed.
Data analyses were performed using SAS version 8.2 (SAS Institute Inc., Cary, NC). All tests were two-sided and performed at the 0.05 significance level. All models were run on the subset of 68 observations that had complete 6 month change data for variables listed above. These models included age, smoking history, baseline and 
